Value2022202320242025TTMSelling/general/admin expenses73.36 M70.45 M61.51 M61.51 M61.51 MResearch & development208.6 M143.62 M151.91 M137 M137 M영업 이익130.53 M-138.05 M-137.11 M-92.55 M-92.55 MNon-Operating Income, Total1.11 M-894 K558 K-559 K-559 KInterest expense, net of interest capitalized—————Non-Operating Income, excl. Interest Expenses1.15 M-1.19 M776 K-610 K-610 KUnusual income/expense-42 K291 K-218 K51 K51 KPretax income135.23 M-119.24 M-116.61 M-79.75 M-79.75 MEquity in earnings—————Taxes10.89 M-568 K6.08 M1.38 M1.38 MNon-controlling/minority interest—————After tax other income/expense—————Net income before discontinued operations124.34 M-118.67 M-122.69 M-81.13 M-81.13 MDiscontinued operations—————Net income124.34 M-118.67 M-122.69 M-81.13 M-81.13 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders124.11 M-118.67 M-122.56 M-81.33 M-81.33 MBasic earnings per share (Basic EPS)1.91-1.72-1.62-1.08-1.08Diluted earnings per share (Diluted EPS)1.9-1.72-1.62-1.08-1.08Average basic shares outstanding65.19 M68.86 M75.85 M75.4 M301.68 MDiluted shares outstanding65.25 M68.86 M75.88 M75.41 M303.79 MEBITDA137.76 M-127.89 M-128.43 M-84.82 M-76.11 MEBIT130.53 M-138.05 M-137.11 M-92.55 M-92.55 MCost of revenue—————Other cost of goods sold—————Depreciation & amortization (cash flow)7.24 M10.16 M8.68 M7.72 M16.44 M
Zymeworks Inc
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.